Haemonetics Corp(HAE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 58.43 | EPS (ttm) | 2.05 | Insider Own | 1.88% | Shs Outstand | 45.5M | Perf Week | 3.12% |
| Market Cap | 5.45B | Forward P/E | 20.59 | EPS next Y | 9.5% | Insider Trans | - | Shs Float | 44.6M | Perf Month | 13.76% |
| Enterprise Value | 6.40B | PEG | 2.01 | EPS next Q | 1.29 | Inst Own | 110.11% | Short Float | 7.68% | Perf Quarter | 40.04% |
| Income | 0.10B | P/S | 4.03 | EPS this Y | 7.12% | Inst Trans | 3.78% | Short Ratio | 4.67 | Perf Half Y | 99.35% |
| Sales | 1.35B | P/B | 6.51 | EPS next 5Y | 10.25% | ROA | 3.99% | Short Interest | 3.43M | Perf YTD | 49.46% |
| Book/sh | 18.41 | P/C | 24.4 | EPS past 3/5Y | -2.9% 5.81% | ROE | 11.2% | 52W High | -3.22% ($123.77) | Perf Year | 142.29% |
| Cash/sh | 4.91 | P/FCF | 18.71 | Sales past 3/5Y | 4.51% 8.91% | ROIC | 4.8% | 52W Low | 144.57% ($48.98) | Perf 3Y | 41.68% |
| Dividend Est. | $1 (0.83%) | EV/EBITDA | 17.86 | EPS Y/Y TTM | -37.48% | Gross Margin | 55.91% | Volatility(W/M) | 2.65% 2.98% | Perf 5Y | 74.34% |
| Dividend TTM | - | EV/Sales | 4.73 | Sales Y/Y TTM | 0.44% | Oper. Margin | 18.37% | ATR (14) | 3.37 | Perf 10Y | 261.47% |
| Dividend Ex-Date | - | Quick Ratio | 1.91 | EPS Q/Q | 2.63% | Profit Margin | 7.12% | RSI (14) | 63.72 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.08 | Sales Q/Q | 5.6% | SMA20 | 3.13% ($116.15) | Beta | 0.65 | Target Price | $124.5 |
| Payout | - | Debt/Eq | 1.4 | Earnings | 2026/11/5 | SMA50 | 9.15% ($109.75) | Rel Volume | 0.76 | Prev Close | $118.32 |
| Employees | 3009 | LT Debt/Eq | 1.4 | EPS/Sales Surpr. | 5.87% 3.51% | SMA200 | 52.76% ($78.42) | Avg Volume(3M) | 0.73M | Price | $119.79 |
| IPO | 1991/5/10 | Option/Short | Yes/Yes | Trades | 6797 | Volume | 558,583 | Change | 1.24% |
A US medical device company that supplies blood and plasma management medical devices. It provides plasma collection systems, hospital hemostasis and blood management solutions, and blood center equipment, with exposure to plasma demand and hospital adoption. A company in the blood and plasma management field.
Over the past 1 year, on the higher side
3% below its 1-year high.
Traded less than usual. That is 76% of its average volume.
Next earnings report: November 5
6 days to go.
HAE makes money exceptionally well
Of every $100 in sales, $18.37 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +7.1% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $2,059. Peers typically go for $1,869. Compared with its own 4-year average, it is 79584% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +74.3%. The S&P 500 did +68% over the same period.
Tap to view numbers
The dividend is on the small side
Pays 0.83% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 110.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #19 of 142 in the industry
Based on market cap of $5B.
FAQ
What kind of company is HAE?
HAE belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of HAE?
The market cap of HAE is approximately $5.5B, ranking 1,316 within its sector.
Does HAE pay dividends?
HAE has a dividend yield of approximately 0.83%, with an annual dividend of $1.00.
What is the P/E ratio of HAE?
HAE has a P/E ratio of approximately 58.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for HAE?
HAE has recorded a 52-week high of $123.77 and a low of $48.98.
